Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2005-04-12
2005-04-12
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C514S184000, C514S185000, C514S186000, C514S187000, C514S188000, C514S290000, C514S291000, C514S292000, C514S492000, C514S822000, C514S824000, C514S863000, C514S883000
Reexamination Certificate
active
06878388
ABSTRACT:
Vanadium compounds useful to prevent and/or inhibit adhesion, migration, and invasion of proliferative cells into surrounding tissue.
REFERENCES:
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 6432941 (2002-08-01), Uckun et al.
patent: 9849173 (1998-11-01), None
patent: WO 9936063 (1999-07-01), None
patent: WO 0027389 (2000-05-01), None
patent: WO 0035930 (2000-06-01), None
Medline Abstract, accession No. 2000239529, abstracting Clinical Cancer Research, vol. 6(4), pp. 1546-1556 (Apr. 2000).*
Albini, A. et al., “Chemotaxis of 3T3 and SV3T3 Cells to Fibroncctin Is Mediated through the Cell-Attachment Site in Fibronectin and a Fibronectin Cell Surface Receptor”,The Journal of Cell Biology,vol. 105, No. 4, pp. 1867-1872 (Oct. 1987).
Brown, L. et al., “Vascular Stroma Formation in Carcinomain Situ, Invasive Carcinoma, and Metastatic Carcinoma of the Breast”,Clinical Cancer Research,vol. 5, No. 5, pp. 1041-1056 (May 1999).
Carbonetto, S. et al., “In Vitro studies on the control of nerve fiber growth by the extracellular matrix of the nervous system”,J. Physiol., Paris,vol. 82, pp. 258-270 (1987).
Carbonetto, S., “Facilitatory and inhibitory effects of glial cells and extracellular matrix in axonal regeneration”Current Opinion in Neurobiology,vol. 1, pp. 407-413 (1991).
Chintala, S. et al., “Invasion of Human Glioma: Role of Extracellular Matrix Proteins”,Frontiers in Bioscience,vol. 1, pp. 324-329 (Nov. 1, 1996).
Djordjevic, C. et al., “Antitumor Activity and Toxicity of Peroxo Heteroligand Vanadates(V) in Relation to Biochemistry of Vanadium”,Journal of Inorganic Biochemistry,vol. 25, pp. 51-55 (Sep. 1985).
Djordjevic, C., “Antitumor Activity of Vanadium Compounds”,Department of Chemistry, The College of William and Mary,Ch. 18, pp. 595-616 (1995).
Dubyak, G., et al. “The Insulin-mimetic Effects of Vanadate in Isolated Rat Adipocytes”,The Journal of Biological Chemistryvol. 255, No. 11, pp. 5306-5312 (Jun. 10, 1980).
Faure, R. et al., “Arrest at the G2/M Transition of the Cell Cycle by Protein-Tyrosine Phosphatase Inhibition: Studies on a Neuronal and a Glial Cell Line”,Journal of Cellular Biochemistry,vol. 59, No. 3, pp. 389-401 (Nov. 1995).
Friedman, H. et al., “Activity of Temozolomide in the Treatment of Central Nervous System Tumor Xenografts”,Cancer Research,vol. 55, No. 13, pp. 2853-2857 (Jul. 1, 1995).
Ghosh, S. et al., “Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents”,Anti-Cancer Drug Design,vol. 14, No. 5, pp. 403-410 (Oct. 1999).
Giese, A. et al., “Substrates for Astrocytoma Invasion”,Neurosurgery,vol. 37, No. 2, pp. 294-302 (Aug. 1995).
Giese, A. et al., “Migration of Human Glioma Cells on Myelin”,Neurosurgery,vol. 38, No. 4, pp. 755-764 (Apr. 1996).
Giese, A. et al., “Glioma Invasion in the Central Nervous System”,Neurosurgery,vol. 39, No. 2, pp. 235-252 (Aug. 1996).
Heylinger, C. et al., “Effect of Vanadate on Elevated Blood Glucose and Depressed Cardiac Performance of Diabetic Rats”,Science,vol. 227, pp. 1474-1477 (Mar. 1985).
Huang, H.-J. et al., “The Enchanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling”,The Journal of Biological Chemistry,vol. 272, No. 5, pp. 2927-2935 (Jan. 31, 1997).
Kopf-Maier, P. et al., “Tumor Inhibition by Metallocenes: Activity against Leukemias and Detection of the Systemic Effect”,European Journal of Cancer,vol. 17, No. 6, pp. 665-669, (Jun. 1981).
Kopf-Maier, P. et al., “Cytokinetic Behavior of Ehrlich Ascites Tumor After in vivo Treatment with cis-Diamminedichloroplatinum(II) and Metallocene Dichlorides”,Journal of Cancer Research and Clinical Oncology,vol. 201, pp. 21-30 (1981).
Kopf-Maier, P. et al., “Induction of Cell Arrest at G1S and in G2After Treatment of Ehrlich Ascites Tumor Cells with Metallocene Dichlorides and cis-Platinum in vitro”,Journal of Cancer Research and Clinical Oncology,vol. 106, No. 1, pp. 44-52 (1983).
Merzak, A. et al., “Adhesion of Human Glioma Cell Lines to Fibronectin, Laminin, Vitronectinand Collagen I Is Modulated by Gangliosides in vitro”,Cell Adhesion&Communication,vol. 3, pp. 27-43 (1995).
Morinville, A. et al., “From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling”,Trends in Pharmacological Sciences,vol. 19, pp. 452-460 (Nov. 1998).
Nagano, N. et al., “Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells”,Acta Neuropathol,vol. 86, No. 1, pp. 117-125 (1993).
Narla, R. et al., 4-(3′-Bromo-4″hydroxylphenyl)-amino-6,7dimethoxyquinazoline: A Novel Quinazoline Derivative with potent Cytotoxic Activity against Human Glioblastoma Cells,Clinical Cancer Research,vol. 4, No. 6, pp. 1405-1414 (Jun. 1998).
Pilkington, G.J., “The role of the extracellular matrix in neoplastic glial invasion of the nervous system”Brazilian Journal of Medical and Biological Research,vol. 29, pp. 1159-1172 (Sep. 1996).
Pilkington, G.J., “In Vitro and in Vivo Models for the Study of Brain Tumour Invasion”,Anticancer Researach,vol. 17, No. 6B, pp. 4107-4110 (Nov.-Dec. 1997).
Rooprai, H. et al., “The role of Integrin Receptors in Aspects of Glioma Invasion In Vitro”,Int. J. Devl. Neuroscience,vol. 17, Nos. 5-6, pp. 613-623 (1999).
Rutka, J. et al., “The extracellular matrix of the central and peripheral nervous systems: structure and function”,J. Neurosurg,vol. 69, pp. 155-170 (Aug. 1988).
Sakurai, H. et al., “Mechanism for a New Antitumor Vanadium Complex: Hydroxyl Radical-Dependent DNA Cleavage by 1, 10-Phenanthroline-Vanadyl Complex in the Presence of Hydrogen Peroxide”,Biochemical and Biophysical Research Communications,vol. 206, No. 1, pp. 133-137 (Jan. 5, 1995).
Schieven, G. et al., “Lineage-specific Induction of B Cell Apoptosis and Altered Signal Transduction by the Phosphotyrosine Phosphatase Inhibitor Bis(maltolato)oxovanadium (IV)”,The Journal of Biological Chemistry,vol. 270, No. 35, pp. 20824-20831 (Sep. 1, 1995).
Schiffer, D. et al., “The vascular response to tumor infiltration in malignant gliomas-morphometric and reconstruction study”,Acta Neuropathol,vol. 77, No. 4, pp. 369-378 (1989).
Schwartz, M., “Role of Trace Elements in Cancer”,Cancer Researach,vol. 35, pp. 3481-3487 (Nov. 1975).
Selbin, J., “The Chemistry of Oxovanadium (IV)”,Chemical Reviews,vol. 65, No. 2, pp. 153-175 (Mar. 25, 1965).
Shechter, Y. et al., “Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions”,Nature,vol. 284, pp. 556-558, (Apr. 10, 1980).
Tolman, E. et al., “Effects of Vanadium on Glucose Metabolism in Vitro”,Life Sciences,vol. 25, No. 13, pp. 1159-1164 (Sep. 24, 1979).
Venstrom, K. et al., “Extracellular Matrix 2: Role of extracellular matrix molecules and their receptors in the nervous system”,The FASEB Journal,vol. 7, pp. 996-1003 (Aug. 1993).
Narla Rama Krishna
Uckun Fatih M
Merchant & Gould P.C.
Pak John
Parker Hughes Institute
LandOfFree
Vanadium compounds for treating proliferative cell disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vanadium compounds for treating proliferative cell disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vanadium compounds for treating proliferative cell disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3414971